The National Cancer Institute (NCI) is ending its support for a 26-year-old push to advance clinical trials for children with ...

Victorian brain cancer researchers have achieved a global-first, using an innovative process to learn how a new drug ...

Several oncology companies announced key trial milestones this week across the landscape of both blood cancers and solid ...

HR-Positive Testing HR-positive breast cancer expresses estrogen receptors (ERs) and/or progesterone receptors (PRs). Testing ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Breakthrough Therapy designation complements Rusfertide’s Orphan Drug and Fast Track designations, which together confer ...

Jody Agena, PharmD, MBA, director of pharmacy operations, Virginia Cancer Specialists, discusses the various responsibilities of the pharmacist within community oncology settings.

A pivotal trial evaluates patritumab deruxtecan for advanced HR-positive, HER2-negative breast cancer, offering hope for ...

Key challenges include shortages in oncology workforce, diagnostic infrastructure, radiotherapy access, and participation in clinical trials. Socioeconomic inequities, stigma, and high out-of-pocket ...

Interested parties can register for and access the live webcast for the H.C. Wainwright conference by visiting the “ Events ” section of the Cardiff Oncology website. The webcast replay will be ...

At the 2025 American Society of Clinical Oncology (ASCO) meeting, the company presented promising early-phase results for two novel breast cancer therapies.